辽宁何氏眼科医院集团股份有限公司 2024年度独立董事述职报告 辽宁何氏眼科医院集团股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人李慧，作为辽宁何氏眼科医院集团股份有限公司（以下简称"公司"） 的独立董事，严格按照《中华人民共和国公司法》《上市公司治理准则》和《上 市公司独立董事管理办法》等法律法规以及《公司章程》的规定，本着客观、公 正、独立的原则，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体 股东尤其是中小股东的合法权益。现将本人 2024 年度履职情况总结如下： 一、基本情况 本人李慧，女，1964 年出生，中国国籍，无境外永久居留权，本科学历， 会计学专业背景。曾任职于沈阳会计师事务所及沈阳华伦会计师事务所（有限公 司）审计助理、经理等；2003 年至今，在辽宁慧佳联合会计师事务所（普通合 伙）任执行事务合伙人；2020 年 4 月至今，在公司担任独立董事。 报告期内，本人未在公司担任除独立董事及董事会专门委员会委员以外的任 何职务，未持有公司股份，未在公司主要股东及其子企业担任任何职务，与公司 及其主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。 ...

辽宁何氏眼科医院集团股份有限公司 2024年度独立董事述职报告 辽宁何氏眼科医院集团股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人朱杰，作为辽宁何氏眼科医院集团股份有限公司（以下简称"公司"） 的独立董事，严格按照《中华人民共和国公司法》《上市公司治理准则》和《上 市公司独立董事管理办法》等法律法规以及《公司章程》的规定，本着客观、公 正、独立的原则，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体 股东尤其是中小股东的合法权益。现将本人 2024 年度履职情况总结如下： 一、基本情况 | 本人 | 2024 | 年度出席董事会会议情况如下： | | --- | --- | --- | | | | 2024 年 委托出席 | | 独立董事 | 年 2024 | 亲自出席 | 委托出席 | 缺席董事 | 是否连续两次 | | --- | --- | --- | --- | --- | --- | | 姓名 | 应参加 | 次数 | 董事会 | 会次数 | 未亲自参加董 | | | 董事会次数 | | 次数 | | 事会会议 | | 朱杰 | 4 | 4 | 0 | 0 | 否 | ...

辽宁何氏眼科医院集团股份有限公司 2024年度独立董事述职报告 辽宁何氏眼科医院集团股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人王厚双，作为辽宁何氏眼科医院集团股份有限公司（以下简称"公司"） 的独立董事，严格按照《中华人民共和国公司法》《上市公司治理准则》和《上 市公司独立董事管理办法》等法律法规以及《公司章程》的规定，本着客观、公 正、独立的原则，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体 股东尤其是中小股东的合法权益。现将本人 2024 年度履职情况总结如下： 一、基本情况 本人王厚双，男，1962 年出生，中国国籍，无境外永久居留权，博士研究 生学历，经济学专业背景。1989 年 7 月至今，在辽宁大学历任世界政治经济与 国际关系教研室讲师、经济学院国际经济与贸易系主任、自由贸易试验区研究院 院长等职务；2020 年 4 月至今，在公司担任独立董事。 报告期内，本人未在公司担任除独立董事及董事会专门委员会委员以外的任 何职务，未持有公司股份，未在公司主要股东及其子企业担任任何职务，与公司 及其主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。 本 ...

前十大流通股东累计持有： 4457.22万股，累计占流通股比： 53.66%，较上期变化： -82.55万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 先进制造产业投资基金(有限合伙) | 1065.17 | 12.82 | 不变 | | 大连东软控股有限公司 | 783.14 | 9.43 | 不变 | | 沈阳新松机器人自动化股份有限公司 | 783.14 | 9.43 | 不变 | | 北京信中利美信股权投资中心(有限合伙) | 521.84 | 6.28 | -55.52 | | 中国工商银行股份有限公司-融通健康产业灵活配置混合 型证券投资基金 | 460.00 | 5.54 | -5.79 | | 共青城鹏信投资管理合伙企业(有限合伙) | 267.39 | 3.22 | -9.22 | | 黄友平 | 254.44 | 3.06 | 6.05 | | 中央企业乡村产业投资基金股份有限公司 | 137.65 | 1.66 | 不变 | | 深圳华大基因（300676）股份有限公 ...

Financial Performance - The company achieved operating revenue of 1,095.63 million yuan, a decrease of 7.56% compared to the same period last year[3]. - The net profit attributable to shareholders was -27.40 million yuan, primarily due to intensified industry competition and the impact of medical insurance payment reform[3]. - The company's operating revenue for 2024 was ¥1,095,633,818.01, a decrease of 7.56% compared to ¥1,185,231,535.43 in 2023[18]. - The net profit attributable to shareholders for 2024 was -¥27,398,159.61, representing a decline of 143.11% from ¥63,551,557.35 in 2023[18]. - The net profit after deducting non-recurring gains and losses was -¥28,787,671.23 in 2024, down 152.03% from ¥55,324,507.19 in 2023[18]. - The net cash flow from operating activities decreased by 11.95% to ¥155,646,834.76 in 2024 from ¥176,771,992.88 in 2023[18]. - Total assets at the end of 2024 were ¥2,225,440,397.53, a decrease of 10.40% from ¥2,483,695,372.45 at the end of 2023[18]. - The net assets attributable to shareholders decreased by 9.42% to ¥1,879,813,770.81 at the end of 2024 from ¥2,075,313,837.01 at the end of 2023[18]. - The company reported a basic earnings per share of -¥0.1734 for 2024, compared to ¥0.4022 in 2023, marking a decline of 143.11%[18]. - The weighted average return on equity was -1.39% in 2024, down from 3.01% in 2023[18]. Investment and R&D - The company has increased investment in innovative business, digitalization, and R&D projects, leading to higher related costs compared to the previous year[3]. - Research and development (R&D) expenditure amounted to ¥18,105,528.86, representing 1.65% of operating revenue, an increase from 1.07% in the previous year[98]. - The number of R&D personnel decreased by 12.41% to 127, with a notable reduction in the number of personnel holding doctoral and master's degrees[94]. - The company is investing in R&D, allocating 10% of its revenue towards developing new technologies and products[172]. - The company has established a collaborative development model integrating medical, educational, and research platforms, focusing on cutting-edge fields such as gene therapy and stem cell regenerative medicine[69]. Market Trends and Industry Insights - The eye health industry is experiencing growth driven by government policies and increased consumer spending, with AI and digitalization enhancing service quality[29]. - The Chinese ophthalmic market has grown from 71 billion RMB in 2015 to 121.28 billion RMB in 2022, with a compound annual growth rate (CAGR) of approximately 8.5%, expected to reach 140.9 billion RMB by 2025[35]. - The overall myopia rate among children and adolescents in China was 51.9% in 2022, with specific rates of 36.7% in primary school, 71.4% in middle school, and 81.2% in high school[36]. - The DRG/DIP payment reform will cover all eligible medical institutions by the end of 2025, significantly reducing medical costs and emphasizing quality improvement in healthcare[38]. - The global ophthalmic AAV gene therapy market is projected to grow from $51 million in 2023 to $353 million by 2030, with a CAGR of 30.5% from 2024 to 2030[42]. Strategic Developments and Future Plans - Future plans and strategic developments mentioned in the report do not constitute a substantive commitment to investors, highlighting the need for risk awareness[4]. - The company aims to shift from traditional diagnosis and treatment to health management, focusing on digital strategies and franchise chains[80]. - The company plans to enhance patient experience and satisfaction through improved digital infrastructure and AI integration[80]. - The company is actively integrating AI technology in healthcare, developing an AI retinal imaging analysis system to assist in diagnosing common eye diseases, improving diagnostic accuracy and efficiency[131]. - The company plans to allocate 1,000 million to the Liaoning Rui Commercial Trade project, with 525.2 million invested, achieving 91.90% of the target[117]. Governance and Management - The company has established a comprehensive internal control system to enhance governance and risk management, aligning with relevant laws and regulations[148]. - The board of directors consists of 7 members, including 1 chairman and 3 independent directors, and has convened 4 meetings with full attendance[146]. - The company has implemented an investor relations management system to facilitate communication and maintain a positive relationship with investors[150]. - The company appointed He Yuehua as the new Chief Financial Officer effective April 1, 2024, following the dismissal of Deng Ming due to management restructuring[161]. - The company has established a multi-level equity incentive system to attract and retain talent, complying with relevant regulations[185]. Challenges and Risks - The company faces risks from external economic uncertainties, including geopolitical tensions and market fluctuations that may impact consumer spending[134]. - Regulatory changes in the healthcare sector pose risks, as new policies could affect market access and operational capabilities[136]. - Increased competition in the eye care industry is anticipated, with a growing number of private eye hospitals and rising public awareness of eye health[137]. - Management risks associated with the company's expansion strategy may arise if internal controls and management practices do not adapt to the growing scale of operations[139]. Social Responsibility and Community Engagement - The company has been recognized for its social responsibility, receiving multiple awards and enhancing its brand reputation[77]. - The company has trained 25 ophthalmology practitioners from 7 developing countries, supporting international eye health initiatives[76]. - The company is focused on enhancing community screening efforts for eye diseases in economically underdeveloped areas[93].

Financial Performance - The company's revenue for Q1 2025 was CNY 291,475,651.27, representing a 2.35% increase compared to CNY 284,795,525.11 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was CNY 32,531,877.20, up 12.27% from CNY 28,976,245.02 year-on-year[4] - Operating profit increased to ¥42,361,044.87, reflecting a growth of 11.43% from ¥37,983,244.96 in the previous period[18] - The total comprehensive income for the current period was ¥31,250,225.55, compared to ¥27,182,272.93 in the previous period, indicating growth[18] - The basic and diluted earnings per share were both ¥0.2059, an increase from ¥0.1834 in the previous period[18] Cash Flow and Investments - The net cash flow from operating activities increased by 36.89% to CNY 79,942,280.03, compared to CNY 58,399,019.66 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥79,942,280.03, compared to ¥58,399,019.66 in the previous period, marking a significant increase[20] - The company reported a net cash outflow from investing activities of ¥323,196,773.08, compared to a smaller outflow of ¥25,303,495.08 in the previous period[20] - The company's cash and cash equivalents decreased to CNY 514,507,643.98 from CNY 767,321,351.31, representing a decline of approximately 32.9%[15] - The company’s cash and cash equivalents at the end of the period were ¥513,584,939.29, down from ¥1,578,132,841.44 at the end of the previous period[21] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2,262,226,831.53, a 1.65% increase from CNY 2,225,440,397.53 at the end of the previous year[4] - The total assets of the company as of March 31, 2025, amounted to CNY 2,262,226,831.53, an increase from CNY 2,225,440,397.53 at the beginning of the period[15] - The company's total liabilities rose to CNY 351,010,403.58 from CNY 345,714,195.13, indicating an increase of approximately 1.0%[16] - The company's inventory decreased to CNY 70,861,668.62 from CNY 74,991,587.59, a decline of approximately 5.5%[15] - The company's non-current assets totaled CNY 791,568,709.65, down from CNY 820,293,209.09, indicating a decrease of about 3.5%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,399, with no preferred shareholders[10] - The company reported a total of 2,722,719 shares in its repurchase account, accounting for 1.72% of the total share capital[12] Financial Challenges - Financial expenses for Q1 2025 increased by 78.91% to CNY -1,243,700, primarily due to a decrease in bank interest[9] - Other income decreased by 52.13% to CNY 660,800, mainly due to a reduction in government subsidies compared to the previous year[9] - The company experienced a 64.63% increase in asset impairment losses, totaling CNY -415,800, primarily due to a decrease in inventory write-down provisions[11] Accounting and Governance - The first quarter report has not been audited[22] - The new accounting standards will be implemented starting in 2025[22] - The board of directors meeting was held on April 24, 2025[23]

Core Viewpoint - He Eye Hospital has decided to terminate the cross-border e-commerce project of Hainan He Eye Color Trading Co., Ltd. due to unsatisfactory performance and market conditions, aiming to enhance the efficiency of fund utilization and protect shareholder interests [1] Group 1 - The project had a total budgeted investment of 26 million yuan [1] - The decision was made during the third board and supervisory board meetings held on April 23, 2025 [1] - Remaining raised funds will be transferred to a special account for excess raised funds and the corresponding special account will be canceled [1]

何氏眼科回复：尊敬的投资者您好，公司注意到近期股价处于低位。股价的波动受多种因素综合影响， 包括宏观经济环境、行业动态、市场情绪等。公司一直高度重视市值管理工作，并采取了一系列措施来 提升公司价值和股东回报：1.聚焦公司战略，稳健经营：公司紧紧围绕发展战略，立足主营业务，深耕 眼科市场，不断深化科技创新，加大消费医疗属性业务占比，积极降本增效。同时密切关注眼科领域的 前沿技术，夯实医疗数字化建设，推动眼科医疗服务向智能化、个性化的方向发展。在业务模式创新 上，探索并推动轻资产业务模式，保持合理的业务的扩张。2.公司以医、教、研三大平台协同发展为基 础，将科技创新作为引擎，围绕视网膜干细胞、视网膜干细胞与肿瘤、眼遗传病学等方面进行深入研 究。3.公司会通过设立的产业基金加快眼科医疗技术创新、眼科器械、眼科药物等眼健康全产业链布 局。4. 践行积极稳健可持续的投资者回报：公司一贯重视股东回报，上市以来，公司已连续三年实施完 成现金分红，累计现金分红约3.25亿元（含税），持续提升投资者回报。5.加强投资者关系管理：通过 多种方式与投资者交流沟通，确保公司内在价值得到充分的传递和展现，多措并举推动市场价值与内在 价 ...

Group 1 - The core viewpoint of the article is the establishment of the Shenyang Clinical Medical Research Center for Diabetic Eye Disease by He Eye Specialist Hospital, which aims to advance research and treatment in diabetic eye diseases [1] - The center will focus on the development of new technologies for prevention, diagnosis, and treatment of diabetes-related eye diseases, including artificial intelligence and genetic testing [1] - A multidisciplinary expert group has been formed, including specialists in internal medicine, ophthalmology, genetic technology, and AI healthcare, to ensure that research is driven by clinical and patient needs [1]

最新一期业绩显示，2024年三季报，公司实现营业收入8.65亿元，同比-8.40%；净利润1637.55万元，同 比-83.53%，销售毛利率40.92%。 4月8日，何氏眼科今日收盘17.49元，上涨3.92%，最新市净率1.43，总市值27.64亿元。 截至2024年三季报，共有34家机构持仓何氏眼科，其中基金34家，合计持股数667.23万股，持股市值 1.34亿元。 辽宁何氏眼科医院集团股份有限公司主营业务为面向眼病患者提供眼科专科诊疗服务和视光服务。公司 的主要服务项目有白内障诊疗服务项目、屈光不正诊疗服务项目、玻璃体视网膜诊疗服务项目青光眼诊 疗服务项目、干眼特色诊疗服务项目、中医特色诊疗服务项目。沈阳何氏眼科医院被评为"国家临床重 点专科"、国际眼科理事会眼科专科医师培训基地、国家药物临床试验机构。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2何氏眼科-141.8643.491.4327.64亿行业平均 45.7141.333.29140.21亿行业中值42.5435.212.4344.57亿1普瑞眼科-184.0323.002.7861.63亿3迪安诊 断-89.9427.081. ...